Nuclear shape, protrusive behaviour and in vivo retention of human bone marrow mesenchymal stromal cells is controlled by Lamin-A/C expression.
Yvonne L DorlandAnne S CornelissenCarlijn KuijkSimon TolMark HoogenboezemJaap Diederik van BuulMartijn A NolteCarlijn VoermansStephan HuveneersPublished in: Scientific reports (2019)
Culture expanded mesenchymal stromal cells (MSCs) are being extensively studied for therapeutic applications, including treatment of graft-versus-host disease, osteogenesis imperfecta and for enhancing engraftment of hematopoietic stem cells after transplantation. Thus far, clinical trials have shown that the therapeutic efficiency of MSCs is variable, which may in part be due to inefficient cell migration. Here we demonstrate that human MSCs display remarkable low migratory behaviour compared to other mesodermal-derived primary human cell types. We reveal that specifically in MSCs the nucleus is irregularly shaped and nuclear lamina are prone to wrinkling. In addition, we show that expression of Lamin A/C is relatively high in MSCs. We further demonstrate that in vitro MSC migration through confined pores is limited by their nuclei, a property that might correlate to the therapeutic inefficiency of administered MSC in vivo. Silencing expression of Lamin A/C in MSCs improves nuclear envelope morphology, promotes the protrusive activity of MSCs through confined pores and enhances their retention in the lung after intravenous administration in vivo. Our findings suggest that the intrinsic nuclear lamina properties of MSCs underlie their limited capacity to migrate, and that strategies that target the nuclear lamina might alter MSC-based cellular therapies.
Keyphrases
- mesenchymal stem cells
- bone marrow
- umbilical cord
- endothelial cells
- cell therapy
- stem cells
- poor prognosis
- clinical trial
- cell migration
- induced pluripotent stem cells
- pluripotent stem cells
- randomized controlled trial
- multidrug resistant
- low dose
- high dose
- gene expression
- dna methylation
- open label
- hematopoietic stem cell